>>> EU's Barnier: Will examine legality of French decree on foreign takeovers un


EU's Barnier: Will examine legality of French decree on foreign takeovers under EU law
- French decree could be a possible limitation on free movement of capital 
- France must notify the measures to the EU 
- EU rules do permit protection of strategic and essential assets 
- National measures must not lead to protectionism 

**Note on May 14th (FR) France govt said to have issued decree to prohibit foreign takeover of strategic firms - financial press - France Industry Min Montebourg said the new 'blocking' measures (adding 5 sectors to the current 11) are considered strategic; considers Alstom as strategic - French press interview

NY Post : David Tepper says ‘The market is dangerous right now’

LAS VEGAS — Billionaire investor David Tepper, the irreverent hedge-fund manager who made more money last year than any of his peers, is getting nervous.
“The market is dangerous right now,” said Tepper, who gained a reputation in late 2008 for his prescient bet that US banks would survive the financial crisis. Last year, his $20 billion Appaloosa Management distressed-debt hedge fund earned a return of almost 40 percent, net of fees — enough to give Tepper a personal $3.5 billion payday.
But the good times could be coming to an end, he said, adding it’s “nervous time.”
Central banks are too complacent these days, Tepper said in a one-on-one interview here with Anthony Scaramucci, the founder of SkyBridge Capital at the SALT conference — the annual get-together of the hedge-fund sector’s heavy hitters that also draws movie stars and politicians, who mix it up with Wall Street’s brightest stars in the freewheeling atmosphere of this desert casino town.
Tepper said the European Central Bank “better ease in June” given the low level of inflation there. “If they don’t, it may be too late,” he warned.
While most of the financial world, and central bankers, have focused on inflation, he said deflation could be worse, pointing to the tepid economic growth more than five years after the financial crisis.
“I’m not saying go short,” he told the investors in the audience. “I’m just saying don’t be too frickin’ long right now.”
Tepper, known for his salty language, cleaned it up for the crowd until he told a story about how his fund’s recent winning streak followed his decision in 2008 to make sure all food banks, shelters and pantries in his home state of New Jersey had enough money to keep going.
“So you believe in karma?” asked Scaramucci.
“Are you f–king kidding me? Of course I believe in that sh-t” replied Tepper.
Tepper started his hedge fund in 1992 after a stint helping put Goldman Sachs’ junk bond operation on the map. The 56-year-old investor, who proudly touts his “inner city” roots, was considered too rough to be named partner. “I couldn’t stand that place,” he said, so he struck out on his own and starting lining up investors for a hedge fund.
An investor who gave him $1 million in 1992 would have $149 million today — one of the best returns in the industry.

>>> AstraZeneca board in line for GBP 60m windfall if Pfizer bid succeeds; Pfize

AstraZeneca board in line for GBP 60m windfall if Pfizer bid succeeds; Pfizer's top scientist to meet with Wellcome Trust 

AstraZeneca’s senior executives would be in line for a GBP 60m (EUR 73m) windfall if a takeover bid from rival pharmaceuticals group Pfizer succeeds, The Times reported. The report said AstraZeneca chief executive Pascal Soriot and 12 other senior executives at the FTSE-100 pharmaceuticals company stand to gain if options and share incentives mature due to a takeover, but did not cite a source for the claim.

Soriot holds options and shares valued at GBP 31m, while his senior colleagues together hold more than 0.5m shares, the item noted.

Separately, the report noted that Soriot said a takeover by Pfizer is “not inevitable". The CEO said AstraZeneca, which is fighting a GBP 63bn takeover by its US rival, is confident about its strategy for independence. AstraZeneca’s defence against Pfizer turned to the geographic challenges the combined company would face, as executives fronted up to Parliament’s Science and Technology Committee yesterday morning, this news service reported on Wednesday.

The Daily Telegraph reported that Pfizer’s leading scientist Mikael Dolsten is visiting the UK to hold meetings with members of the country’s science community. It is understood that Dolsten held a meeting yesterday, 14 May with the chairman of the Wellcome Trust, William Castell, the item said. Dolsten also intends to hold a meeting with the president of the Royal Society, Paul Nurse, the article added, noting that both Nurse and Castell have voiced concerns about Pfizer’s bid for AstraZeneca.

In the meantime, AstraZeneca continued its recent campaign to update the market on the health of its drug pipeline. Below is an excerpt from a company announcement, the full version of which can be read here.

New data from AstraZeneca's investigational cancer medicines demonstrate the rapid progression of its oncology pipeline. Over 40 scientific abstracts from AstraZeneca and its global biologics R&D arm MedImmune will be featured at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the end of this month.

Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca said: "We believe that our rich oncology pipeline has the potential to redefine the way that cancer patients are treated. We continue to deliver on our late stage assets and drive our scientific leadership in oncology, as clearly demonstrated by the recent accelerated development of key assets.

"The preliminary data made available today highlight our strength across our three core areas of oncology research: immuno-oncology, our focus on the genetic drivers of cancer and acquired resistance and DNA damage repair. We are looking forward to the presentation of the full data sets at ASCO."


Source The Times (London), Daily Telegraph, Company website

>>> Alstom: government working on French consortium including CDC, Areva, Thales

Alstom: government working on French consortium including CDC, Areva, Thales and Safran; Thales rejects claim – reports (translated)

The French government is understood to be trying to set up an alternative to the proposed EUR 12.35bn sale of the energy operations of Alstom to listed Connecticut-based conglomerate General Electric (GE), French weekly La Lettre de L’Expansion reported. The unsourced report said that French Finance and Economy Minister Arnaud Montebourg is believed to be busy creating a consortium of French companies that could involve industrial groups Areva, Thales and Safran, as well as state-owned financial services group Caisse des Depots et Consignations (CDC). The report claimed that Thierry Breton has been acting as the adviser to Montebourg on that matter.

This development was also reported in daily Les Echos, which referred to comments made by Thales chairman and chief executive Jean-Bernard Levy, who denied that his group was involved in the matter and that Montebourg had contacted Thales.

He then added that Thales was looking for opportunities to acquire businesses, especially companies operating in the railway signaling sector.


Source La Lettre de l'Expansion, Les Echos

>>> What to look at today

US Market closed Lower, Small cap leaded the move ( Russel 2000 -1,6%), Out of the five largest sectors that represent more than 70.0% of the S&P500, consumer discretionary (-1.1%), financials (-0.8%), technology (-0.6%), and industrials (-0.8%) lagged throughout the session, while health care (unch) displayed relative strength thanks to modest gains in biotech. The iShares Nasdaq Biotechnology ETF (IBB 231.41, +0.90) advanced 0.4%. The weakest sector of the day—consumer discretionary—suffered from noteworthy losses among apparel retailers. Shares of Fossil (FOSL 100.00, -11.45) tumbled 10.3% after the company's cautious guidance overshadowed its earnings beat. Volume were belwo average @ 600mil shares... Japan Q1 GDP grew at a 3-year high of 5.9% on annual basis, as consumers rushed to make advance purchases before the Apr 1st start of higher sales tax and businesses invested generously...- Shanghai Composite remains under pressure on renewed concerns over China's
rate of growth in the wake of disappointing April economic data. China National...Nikkei -1,07% HS+0,35%...Shanghai -0,70%

Eur$ S&P Fut flat European fut -0,10%

Macro
- French Govt Publishes Decree on Foreign Investment, French Decree Lets Govt Block Some Foreign Takeovers

Keep an eye on :
- AN FP : Mediaset Seeks Financing to Boost Canal+ Stake, Expansion Says
- AGL IM : Autogrill PT Cut to EU8.5 at Mediobanca; Kept at Outperform
- AGN NA : Aegon 1Q Underlying Pre-Tax Profit Beats Analysts' Estimates
- CFR VX : Richemont FY Oper. Profit In Line With Ests. April Sales Hurt by Japan, Div. Beats Forecast
- G IM : Generali 1Q Net Income Rises to EU660m; Beats EU606.1m Estimate
- IM NA : Imtech 1Q Net Loss EU77.7m vs EU60.9m Loss
- LNZ AV : Lenzing 1Q Sales, Ebit Drop; Cost Cut Program Exceeding Target
- M5Z GY : Manz 1Q Sales Rise 9%, Loss Widens; Says Got New Orders of EU75m
- MRK GY : Merck KGaA 1Q Rebif Sales Beat Ests.; Erbitux Sales Miss
- UG FP : Peugeot Family Won’t Withdraw From Carmaker, Member Tells Echos
- SIX2 GY : Sixt 1Q Sales Rise 8%; Pretax Up 19%; Confirms 2014 Outlook
- SZG GY : Salzgitter 1Q Loss EU13.3m vs EU17.1m Loss, Confirms Forecast
- TKA AV : America Movil Starts Public Offer in Cash for Telekom Austria
- VIV FP : Vivendi 1Q Sales in Line, Adj. Net Income Beats Estimates, 1Q Adj. Net Beats, Says It's Primed for Growth
- VK FP : Vallourec to Cut 240 Jobs in France, Germany: Les Echos
- VTG LN : VTG 1Q Sales, Ebit, Pretax Fall; Cuts 2014 Sales Outlook
- WDI GY : Wirecard 1Q Sales Miss Est., Ebitda Up 33%; Confirms Outlook
- ZURN VX : Zurich Insurance 1Q Net $1.27b vs $1.06b

>>> BRokers Upgrades & Downgrades

>>> Up
*ARKEMA RAISED TO OVERWEIGHT VS NEUTRAL AT JPMORGAN
*ISBANK RAISED TO EQUALWEIGHT VS UNDERWEIGHT AT MORGAN STANLEY

>>> Down
*IMPLATS CUT TO EQUALWEIGHT VS OVERWEIGHT AT MORGAN STANLEY
*LEROY SEAFOOD CUT TO BUY VS STRONG BUY AT NORDEA
*LONMIN CUT TO NEUTRAL VS BUY AT CITI
*ROLLS-ROYCE CUT TO UNDERPERFORM VS MARKET PERFORM AT BERNSTEIN
*SARAS CUT TO SELL VS HOLD AT SOCGEN
*STATOIL ASA CUT TO SECTOR PERFORM FROM TOP PICK AT RBC CAPITAL
*TOTAL CUT TO SECTOR PERFORM FROM OUTPERFORM AT RBC CAPITAL
*VODAFONE CUT TO NEUTRAL VS BUY AT GOLDMAN

>>> PT change
*CAMPARI PT CUT TO EU5.9 VS EU5.92 AT JPMORGAN; KEPT AT NEUTRAL
*FIAT PT CUT TO EU6.6 VS EU6.9 AT CITI; KEPT AT SELL
*MARR PT RAISED TO EU15.5 VS EU14.5 AT BOFAML; KEPT AT BUY
*MEDIASET PT CUT TO EU4.7 VS EU5 AT DEUTSCHE BANK; KEPT AT BUY
*SARAS PT CUT TO EU1.05 VS EU1.1 AT UBS; KEPT AT SELL

>>> Initiation
*ASOS RATED NEW BUY AT BERENBERG; PT 5,350P
*DEBENHAMS RATED NEW HOLD AT BERENBERG; PT 87P
*FORTUM RATED NEW SELL AT SOCGEN; PT EU13.3
*GLAXO RATED NEW OVERWEIGHT AT MORGAN STANLEY, PT 1,950P
*MARKS & SPENCER RATED NEW HOLD AT BERENBERG; PT 415P
*SUPERGROUP RATED NEW BUY AT BERENBERG; PT 1,490P

>>> Call
>> Stock
*ICAP ADDED TO UBS’S LEAST PREFERRED LIST
*GDF Suez, Enel Preferred Among Large Cap Utilities at JPMorgan

(BFW) French Govt Publishes Decree on Foreign Investment


French Govt Publishes Decree on Foreign Investment
2014-05-15 00:08:49.553 GMT


By Jim Silver
     May 15 (Bloomberg) -- Decree updates the fields that
require govt authorization for foreign investment, covering
“essential activities” for the national interest, according to
today’s official govt gazette.
  * Decree amends existing law to cover providers of energy,
    water; operators of transport services, networks; operators
    of electronic communications services, networks; operation
    of installations of “vital importance”
  * NOTE: Earlier, French Decree Lets Govt Block Some Foreign
    Takeovers: Reuters


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editor responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net